Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 344.70 Billion |
| Market Size (2030) | USD 501.57 Billion |
| CAGR (2025 - 2030) | 7.79% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market Analysis
The Biopharmaceutical Contract Research And Manufacturing Services Market size is estimated at USD 344.70 billion in 2025, and is expected to reach USD 501.57 billion by 2030, at a CAGR of 7.79% during the forecast period (2025-2030).
Driven by the rising trend of outsourcing, the complexities of drug development, a strategic emphasis on core competencies, regulatory pressures, and the mounting burden of chronic diseases, the biopharmaceutical contract research and manufacturing services (CRAMS) market has witnessed significant growth. Outsourcing enables pharmaceutical companies to optimize costs and concentrate on their core strengths.
As drug development processes grow increasingly complex and the demand to adhere to regulatory guidelines intensifies, outsourcing has emerged as a pivotal strategy. This trend is further fueled by the expanding CRAMS industry and the rising adoption of advanced research and manufacturing services. For instance, in October 2024, Thermo Fisher Scientific introduced its Accelerator Drug Development, a comprehensive suite of solutions encompassing contract manufacturing and research. This initiative aims to transform the pharmaceutical value chain by catering to both biotech firms and major pharmaceutical companies. With tailored services for small molecules, biologics, and advanced therapies such as cell and gene treatments, Accelerator Drug Development supports clients throughout the entire drug development lifecycle, from initial research to final development. The rising demand for outsourced research and manufacturing services is prompting market players to leverage these opportunities, a trend expected to sustain market expansion.
Additionally, the increasing prevalence of chronic diseases is anticipated to drive demand for advanced drug treatments, thereby boosting research and development activities in the pharmaceutical sector and propelling market growth over the forecast period. As per the January 2024 update by the European Centre for Disease Prevention and Control (ECDC), over six million dengue cases were reported from 92 countries/territories in 2023 in Europe. Similarly, According to Alzheimer’s Disease Facts and Figures Annual Report 2023, more than 6 million Americans are living with Alzheimer’s disease and this number is projected to rise to nearly 13 million by 2050. The growing incidence of chronic conditions necessitates the development of innovative, targeted therapies, compelling pharmaceutical companies to enhance their R&D and manufacturing processes. This demand for precision medicine and biologics, such as monoclonal antibodies and gene therapies, is anticipated significantly expanded CRAMS services.
Moreover, to address the rising demand in the biopharmaceutical CRAMS sector, industry players are expanding their service portfolios through strategic partnerships, acquisitions, and investments, which is expected to boost the market growth in the coming years. For instance, in Septe,ber 2023, Orchid Pharma Limited a CRAMS has inked a manufacturing sublicense deal with Global Antibiotic Research & Development Partnership (GARDP) to produce Cefiderocol, an antibiotic targeting specific Gram-negative infections. This fresh pact is set to enhance antibiotic accessibility for countless patients in areas grappling with elevated rates of antimicrobial resistance (AMR). Such collaborations, which provide integrated services ranging from early-stage research to large-scale manufacturing, are expected to drive market growth.
As chronic diseases become more prevalent and outsourcing trends rise, the demand for biopharmaceutical CRAMS services has surged. In response, industry players are strategically expanding their geographic reach, integrating advanced technologies, and forging key partnerships to cater to the growing demand for biologics. These strategic initiatives are expected to optimize service delivery, enhance competitive advantage, and drive robust growth in the Pharmaceutical CSO market during the forecast period
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market Trends
Manufacturing Segment is Expected to Hold a Significant Share Over the Forecast Period
Contract manufacturers are increasingly being engaged for specialized services in the production and manufacturing of biopharmaceuticals. These services include the production of active pharmaceutical ingredients (APIs), formulation, and packaging, encompassing biologics and biosimilars. The growth of this segment is driven by factors such as increasing demand for biopharmaceuticals, rising investments in research and development (R&D), and cost efficiencies achieved through outsourcing.
To optimize operational costs and enhance efficiency, biopharmaceutical companies are leveraging outsourcing strategies. This approach enables them to avoid significant capital expenditures associated with building and maintaining production facilities. For instance, in May 2023, GenScript Biotech Corporation, a contract research organization (CRO), expanded its primary manufacturing facility in Zhenjiang, Jiangsu, China. The expansion included the addition of four new dynamic axial compression columns, increasing the average monthly production capacity for large-scale peptides to over 5kg. Furthermore, 32 square feet of freeze dryers were incorporated to support the mass freeze-drying process. As a result of these developments, drug manufacturers are likely to increase dependence on outsourcing services, fueling the market's expansion.
Technological advancements, such as single-use bioreactors, continuous manufacturing, and automation, have significantly enhanced the efficiency, scalability, and cost-effectiveness of drug production. Innovations in biopharmaceuticals, particularly through contract research and manufacturing services (CRAMS), are transforming drug development. Advanced technologies, including AI, bioprinting, and automation, are streamlining both research and manufacturing processes. For example, in August 2024, BiBo Pharma, based in Boston, introduced a cutting-edge ultra-large production platform. This platform features a 30,000L stainless steel bioreactor and boasts a total capacity exceeding 40,000 liters. This biomanufacturing advancement reduces the global average cost of antibody-drug production from several hundred dollars to just USD 10 per gram, creating a lucrative opportunity for biopharmaceutical companies worldwide. Given these manufacturing advancements offered by CRAMS, the sector is set for substantial growth, providing enhanced production capabilities and cost efficiencies essential for meeting the surging global demand for biopharmaceuticals.
Moreover, global market players are aligning their services with diverse regional regulatory requirements and market demands, driving market expansion. For instance, in November 2024, SyVento Biotech inaugurated a cutting-edge mRNA manufacturing facility. Cytiva's FlexFactory features laboratories, production zones, offices, and shared spaces. This strategic initiative enables SyVento Biotech, a Contract Development and Manufacturing Organization (CDMO), to enhance and expedite its service offerings. Thus, expansion of contract manufacturing services is expected to increase its adoption is likeky to support the segment growth over the forecast period.
Additionally, in September 2023, Ind-Swift Laboratories Limited approved the transfer of its active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs Private Limited. Synthimed, a portfolio company under the India Resurgence Fund, is making significant strides in the contract manufacturing industry is likely to propel the segment growth over the forecast period.
In conclusion, as biopharmaceutical companies increasingly rely on external partners to address production challenges, the manufacturing segment of the CRAMS market is positioned for sustained growth. With biologics and new therapies dominating the market, CRAMS providers are well-placed to deliver critical services, ranging from drug development to large-scale manufacturing.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America holds a prominent position in the Biopharmaceutical Contract Research and Manufacturing Services (CRAMS) market. This dominance is driven by the region's well-established biopharmaceutical industry, advanced infrastructure, and a strong focus on research and development. The United States and Canada are the key contributors to the growth of this segment, supported by favorable government initiatives, a skilled workforce, and the presence of leading biopharma companies and CRAMS providers.
North America is home to some of the largest biopharmaceutical companies in the world, such as Pfizer, Amgen, Moderna, and AbbVie, which generate significant demand for contract manufacturing services. These companies increasingly outsource manufacturing to CRAMS providers to streamline operations and reduce costs. For instance, in September 2024, Simtra BioPharma Solutions is set to invest over USD 250 million in expanding its sterile fill/finish manufacturing campus located in Bloomington, Indiana. The expansion will see the construction of a new 150,000 square foot facility. This facility will feature two high-speed automated isolator syringe fill lines, alongside a new high-speed isolator vial line, which will be complemented by three 30 square meter lyophilizers. Furthermore, every process suite within the new building will include dedicated formulation and compounding rooms.
The growing prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders is fueling demand for biologics and biosimilars in the region. This demand requires sophisticated manufacturing processes, which are often outsourced to specialized CRAMS providers like Lonza, Thermo Fisher Scientific, and Catalent. For instance, according to the article published in Jouranl of Cardiac Health in September 2024, around 6.7 million Americans aged 20 and older grapple with heart failure (HF) in 2022. Projections indicate this number will swell to 8.7 million by 2030, 10.3 million in 2040, and reach 11.4 million by 2050 in the United States.
CRAMS providers in North America are increasingly focusing on high-value therapeutics such as personalized medicines, gene therapies, and biosimilars. This focus ensures competitive differentiation and aligns with market demands. For instance, in January 2024, AbbVie and Umoja Biopharma (Umoja) inked two exclusive option and license agreements, aiming to harness Umoja's proprietary VivoVec platform for developing multiple in-situ generated CAR-T cell therapy candidates in oncology. Under the first agreement, AbbVie secures an exclusive option to license Umoja's CD19-directed in-situ generated CAR-T cell therapy candidates.
In conclusion, North America remains a leader in the CRAMS manufacturing segment, with a focus on innovation, regulatory excellence, and strategic growth. The region's biopharma ecosystem and emphasis on cutting-edge technologies position it as a critical hub for contract manufacturing services, ensuring sustained growth in the years to come.
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Industry Overview
The biopharmaceutical CRAMS market is moderately competitive and consists of several significant players. The market players are engaged in strategic development and collaboration to expand the market share. Major players like Catalent Inc. Wuxi Biologics, Samsung Biologics, Lonza, IQVIA, are actively acquiring companies to strengthen their foothold in the global market.
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market Leaders
-
Catalent Inc.
-
Samsung Biologics
-
Lonza
-
Wuxi Biologics
-
IQVIA
- *Disclaimer: Major Players sorted in no particular order
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market News
- November 2024: BioPharmaSpec has unveiled three new facilities across Europe. These state-of-the-art centers will specialize in discovery and R&D services, providing in-depth structural and physicochemical characterization for a diverse range of biopharmaceuticals. Their expertise spans monoclonal antibodies, antibody-drug conjugates, cell and gene therapies, bioactive peptides, oligonucleotides, and carbohydrates. Additionally, the facilities will focus on HCP identification and quantifying other pertinent product- and process-related impurities.
- August 2024: Pfizer Inc has unveiled two research initiatives in collaboration with Quotient Therapeutics, a company founded by Flagship. Together, the firms will scrutinize somatic mutations present in the tissues of affected patients, aiming to guide the discovery and development of groundbreaking therapies for cardiovascular and renal ailments.
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Industry Segmentation
As per scope of the report, biopharmaceutical CRAMS (Contract Research and Manufacturing Services) refers to the outsourcing of research, development, and manufacturing activities by biopharmaceutical companies to third-party service providers. These service providers specialize in areas like drug discovery, clinical trials, formulation, and large-scale production of biopharmaceuticals, including biologics and biosimilars.
The biopharmaceutical contract research and manufacturing services (CRAMS) market is segmented by service type, therapeutics area, end-user, and geography. By service type, the market is segmented as manufacturing and research. By therapeutics area, cardiovascular, infectious diseases, endocrine diseases, oncology, gastrointestinal, and others. By end-user, the market is segmented as pharmaceutical and biopharmaceutical companies, medical device companies, and others. The other end-user segment includes academic and research institutes, and cosmeceutical companies, among others. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market sizing and forecasts have been done on the basis of value (in USD).
| By Service Type | Manufacturing | ||
| Research | |||
| By Therapeutic Area | Cardiovascular | ||
| Infectious Diseases | |||
| Endocrine Diseases | |||
| Oncology | |||
| Gastrointestinal | |||
| Others (Neurological Diseases, and Autoimmune Diseases, Among Others) | |||
| By End-User | Pharmaceutical and Biopharmaceutical Companies | ||
| Medical Device Companies | |||
| Others (Academic and Research Institutes, Cosmeceutical Companies, Among Others) | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Manufacturing |
| Research |
| Cardiovascular |
| Infectious Diseases |
| Endocrine Diseases |
| Oncology |
| Gastrointestinal |
| Others (Neurological Diseases, and Autoimmune Diseases, Among Others) |
| Pharmaceutical and Biopharmaceutical Companies |
| Medical Device Companies |
| Others (Academic and Research Institutes, Cosmeceutical Companies, Among Others) |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Market Research FAQs
How big is the Biopharmaceutical Contract Research And Manufacturing Services Market?
The Biopharmaceutical Contract Research And Manufacturing Services Market size is expected to reach USD 344.70 billion in 2025 and grow at a CAGR of 7.79% to reach USD 501.57 billion by 2030.
What is the current Biopharmaceutical Contract Research And Manufacturing Services Market size?
In 2025, the Biopharmaceutical Contract Research And Manufacturing Services Market size is expected to reach USD 344.70 billion.
Who are the key players in Biopharmaceutical Contract Research And Manufacturing Services Market?
Catalent Inc., Samsung Biologics, Lonza, Wuxi Biologics and IQVIA are the major companies operating in the Biopharmaceutical Contract Research And Manufacturing Services Market.
Which is the fastest growing region in Biopharmaceutical Contract Research And Manufacturing Services Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Biopharmaceutical Contract Research And Manufacturing Services Market?
In 2025, the North America accounts for the largest market share in Biopharmaceutical Contract Research And Manufacturing Services Market.
What years does this Biopharmaceutical Contract Research And Manufacturing Services Market cover, and what was the market size in 2024?
In 2024, the Biopharmaceutical Contract Research And Manufacturing Services Market size was estimated at USD 317.85 billion. The report covers the Biopharmaceutical Contract Research And Manufacturing Services Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Biopharmaceutical Contract Research And Manufacturing Services Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) Industry Report
Statistics for the 2025 Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Biopharmaceutical Contract Research And Manufacturing Services (CRAMS) analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
